Note: The 60-month progression-free rates and the hazard ratio of 0.55 are from the 64-month PFS tab of the MAIA efficacy page; the Prescribing Information reports the 64-month medians.
Do patients live longer on Darzalex with lenalidomide and dexamethasone (MAIA)?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)
Note: The 60-month and 89-month survival percentages are from the MAIA efficacy page (the 89-month figure from its 89-month OS tab); the Prescribing Information reports the 89-month medians.
What response and MRD-negativity rates did Darzalex (DRd) achieve in MAIA?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)
Note: Table 23 columns are DRd (N=368) and Rd (N=369), in that order. The MAIA efficacy page reports the response and MRD results at a median follow-up of 28 months.
What MRD-negativity and complete response rates did Darzalex Faspro with VRd achieve (CEPHEUS)?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)
Note: Table 29 columns are DARZALEX FASPRO-VRd (N=197) and VRd (N=198), in that order. Footnotes f, c, and m date each row to the primary (22-month), interim (39-month), or final (59-month) analysis.
Does Darzalex Faspro with VRd delay myeloma progression in transplant-ineligible patients (CEPHEUS)?
Applies to Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)
Note: Table 29 columns are DARZALEX FASPRO-VRd (N=197) and VRd (N=198), in that order. The CEPHEUS efficacy page also shows a 59-month final analysis as a graphic.
Does Darzalex Faspro with VRd delay myeloma progression in transplant-eligible patients (PERSEUS)?
Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)
Note: The hazard ratio is from the AQUILA summary that the Darzalex HCP site links. Table 35 columns are DARZALEX FASPRO (n=194) and active monitoring (n=196), in that order.
Subgroup results
Does Darzalex Faspro with VRd lower progression risk in high-risk cytogenetics (PERSEUS post hoc)?
Applies to Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DVRd vs VRd, post hoc cytogenetic subgroup analysis of PERSEUS